Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy
NCT02046733Phase 2Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Dec 2015
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in small cell lung cancer (SCLC), sponsored by ETOP IBCSG Partners Foundation. Started Dec 2015; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02046733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02046733.